ClinicalTrials.gg
CompletedNCT00784810Updated Nov 2, 2011Results posted

A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis

A Phase 4 interventional study of Oxycodone/Naloxone and Codeine/Paracetamol in Osteoarthritis and Back Pain, sponsored by Napp Pharmaceuticals Limited. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-11-02.

Sponsored by Napp Pharmaceuticals Limited · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 167 studies in Osteoarthritis with a site in United Kingdom — 14 open to participants now, 38 under way, 1 of them phase 3. Osteoarthritis · United Kingdom.

Enrollment
30th of 114
247 · median 108
Started
2009
with 8 others
Phase 4
16 of 167
none open now
Registered
23rd of 167
by date

Among the 167 studies in Osteoarthritis with a site in United Kingdom, this one is the 30th largest by enrollment of the 114 interventional ones that give a count, is one of 9 that started in 2009, is one of 16 in phase 4, and was the 23rd registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

14 of the 167 studies in Osteoarthritis with a site in United Kingdom are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Osteoarthritis with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to compare oxycodone/naloxone combination tablet and codeine/paracetamol tablets in the treatment of moderate to severe chronic low back pain or pain due to osteoarthritis.

Read the detailed description

This is a randomised, double-blind, double-dummy, parallel group, 12-week study to assess the efficacy and tolerability of oxycodone/naloxone compared to codeine/paracetamol tablets in the treatment of moderate to severe chronic low back pain or moderate to severe pain due to OA of the hip and /or knee.

The screening period will be 3 - 7 days duration. If a subject meets all the screening criteria they may enter the Run-in Period.

During the screening period subjects will continue to take their pre-study pain medication.

The run-in period will be 7 - 14 days duration. During the run-in period subjects will continue to take their pre-study pain medication.

Visit 3 will occur at the end of the Run-in Period (7-14 days after Visit 2). To qualify for entry into the treatment period of the study, subjects must have uncontrolled pain as shown by average daily pain scores of >5 on 4 of the last 7 days of the run in period.

Eligible subjects will be randomised to either oxycodone/naloxone or codeine/paracetamol tablets. Subjects will receive double-blind study medication for up to 12 weeks.

03

Conditions studied

  • Osteoarthritis
  • Back Pain

Keywords

  • Efficacy, tolerability, moderate/severe, oxycodone/naloxone
  • codeine/paracetamol, chronic low back pain, osteoarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects at least 18 years or older.
  2. Female subjects less than one year must have a negative urine pregnancy test recorded prior to the first dose of study medication, be non-lactating, and willing to use adequate and reliable throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilization, implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner.
  3. Subjects with a clinical diagnosis of degenerative or primary OA whose primary pain site is of the hip(s) and/or knee(s) and that require around-the-clock opioid therapy in which the diagnosis may be supported by evidence such as one of the following: MRI, CAT, arthroscopy or x-ray. The clinical imaging of OA may include one or more of the following features: joint space narrowing, degenerative changes, osteophyte formation or subchondral cysts. Subjects will identify the most painful joint (hip or knee) for documentation of OA. Pain measurement will be done at this joint only.
  4. Subjects with moderate to severe chronic low back pain e.g osteoarthritis, spinal stenosis, spondylolisthesis, failed back surgery, scoliosis, discogenic disorders such as herniated disc.
  5. Subjects who are currently receiving codeine/paracetamol combination tablets up to a maximum dose of 120 mg codeine per day or tramadol up to a maximum dose of 100 mg/day or dihydrocodeine / paracetamol tablets up to a maximum dose of 120 mg dihydrocodeine per day.
  6. Subjects willing and able to participate in all aspects of the core study, including use of oral medication, completion of subjective evaluations, attending scheduled clinic visits, completing telephone contacts, and compliance with protocol requirements as evidenced by providing written, .
  7. Subjects in which the pre-study, non-opioid analgesics, and all other concomitant medications, including those medications for the treatment of depression are anticipated to remain stable throughout the treatment phase of the study.

Exclusion criteria

Exclusion Criteria:

  1. Any history of to oxycodone, naloxone, codeine, ibuprofen, bisacodyl or related products and ingredients.
  2. Any to oxycodone, naloxone, codeine, paracetamol or ibuprofen.
  3. Subjects with evidence of significant structural abnormalities of the GI tract (e.g., bowel obstruction, strictures) or any diseases/conditions that affect bowel transit (e.g., ileus, hypothyroidism).
  4. Subjects with cancer associated pain.
  5. Subjects with secondary osteoarthritis (e.g. fracture, septic, acromegaly etc.).
  6. Active alcohol or drug abuse and/or history of opioid abuse.
  7. Subjects with Rheumatoid Arthritis.
  8. Subjects with non opioid induced constipation.
  9. Subjects with evidence of clinically unstable disease, as determined by medical history, clinical laboratory tests, results, and physical examination that, in the investigator's opinion, preclude entry into the study.
  10. Subjects with evidence of impaired liver/kidney function upon entry into the study defined as: , alanine aminotransferase, or alkaline phosphatase levels >3 times the ; Gamma glutamyl transpeptidase ≥5 times the upper limit of normal; Total level outside of the reference range unless the value is associated with pre documented Gilbert's Syndrome; Creatinine level outside of the reference range or > 2 mg/dl unless after discussion with the Medical Monitor it is confirmed the subject does not have renal impairment that would preclude the subject's inclusion in the study; In the investigator's opinion the subject has liver and/or kidney impairment to the extent that the subject should not participate in this study.
  11. Subjects who have required treatment for the diagnosis of IBS.
  12. Subjects receiving hypnotics or other CNS depressants that, in the investigator's opinion, may pose a risk of additional CNS depression with opioid study medication.
  13. Subjects with a history of depression or other psychiatric disorder that in the opinion of the investigator is significant enough to exclude the subject from the study.
  14. Subjects who are currently involved in legal action regarding their pain condition or subjects in which their pain condition may be of a psychiatric nature.
  15. Subjects receiving opioid substitution therapy for opioid addiction (e.g., methadone or buprenorphine).
  16. Subjects presently taking, or who have taken naloxone or naltrexone within 30 days of study entry (defined as the start of the Screening Period).
  17. Surgery within 2 months prior to the start of the Screening Period, or planned surgery during the12-week treatment period that may affect GI motility or pain levels.
  18. Subjects who have received a new chemical entity or an experimental drug within 30 days of study entry (define as the start of the Screening Period).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    Oxycodone/Naloxone Tablets

    Oxycodone/Naloxone combination

    Drug: Oxycodone/Naloxone

  • Active comparator
    Codeine/Paracetamol Tablets

    Codeine/Paracetamol combination

    Drug: Codeine/Paracetamol

Interventions

  • DrugOxycodone/Naloxone

    Drug pages: Oxycodone · Naloxone

    5/2.5, 10/5 and 20/10 mg oxycodone/naloxone combination, 12 hourly

  • DrugCodeine/Paracetamol

    Drug pages: Codeine · Acetaminophen

    15/500 and 30/500 mg codeine/paracetamol tablets, 2 tablets 6 hourly

06

What researchers measure

Primary outcomes

  1. Average Daily Pain Score Box Scale-11 (BS-11) Recorded at Week 12 (Average Pain Over Last 24 Hours)

    The primary objective was to demonstrate non inferiority of Oxycodone/Naloxone Prolonged Release (OXN PR) compared to codeine/paracetamol in moderate to severe pain as assessed by BS-11 average daily pain scores. The Box Scale-11 is a scale from 0 to 10 (i.e. 0, 1, 2...10), where the subject records their daily pain over the previous 24 hours, by circling the relevant box, where 0 = no pain and 10 = pain as bad as you can imagine. This value is the value recorded at week 12 (average pain over the last 24 hours)

    Time frame: Average daily pain over last 24 hours (at Week 12)

Secondary outcomes

  1. Number of Intakes of Rescue Medication (Ibuprofen) Between Visit 8 and Visit 9 for the 2 Groups.

    To compare the number of intakes of rescue medication use (ibuprofen) for breakthrough pain between OXN (Oxycodone/Naloxone) and codeine/paracetamol groups. Ibuprofen tablets (400mg up to 3 times per day) were available as rescue medication. This was recorded by the subject in their diary whenever it was taken. The discrepancy in numbers of patients at this stage (between Visit 8 and Visit 9) is due to subject withdrawal during the study. The mean values presented are the "number of intakes of rescue medication" for this period (ie between Visit 8 and Visit 9).

    Time frame: Between visit 8 and 9

07

Results

Posted Nov 2, 2011

Participant flow

Patients were recruited in primary and secondary care in the UK from 6 Feb 2009 to 24 Mar 2010

Participant flow — Overall Study
MilestoneOxycodone/Naloxone Tablets (OXN)Codeine/Paracetamol Tablets
Started124123
Completed6174
Not completed6349
Withdrew: Adverse event3220
Withdrew: Lack of efficacy1411
Withdrew: Withdrawal by subject119
Withdrew: Administrative58
Withdrew: Lost to follow-up11

Outcome measures

PrimaryAverage Daily Pain Score Box Scale-11 (BS-11) Recorded at Week 12 (Average Pain Over Last 24 Hours)

The primary objective was to demonstrate non inferiority of Oxycodone/Naloxone Prolonged Release (OXN PR) compared to codeine/paracetamol in moderate to severe pain as assessed by BS-11 average daily pain scores. The Box Scale-11 is a scale from 0 to 10 (i.e. 0, 1, 2...10), where the subject records their daily pain over the previous 24 hours, by circling the relevant box, where 0 = no pain and 10 = pain as bad as you can imagine. This value is the value recorded at week 12 (average pain over the last 24 hours)

Time frame:
Average daily pain over last 24 hours (at Week 12)
Reported as:
Mean · Units on a BS-11 scale at Week 12
Average Daily Pain Score Box Scale-11 (BS-11) Recorded at Week 12 (Average Pain Over Last 24 Hours)
Units on a BS-11 scale at Week 12Oxycodone/Naloxone Tablets (OXN)Codeine/Paracetamol Tablets
Average Daily Pain Score Box Scale-11 (BS-11) Recorded at Week 12 (Average Pain Over Last 24 Hours)4.2 ± 2.1394.64 ± 2.046
Statistical analysis
  • Oxycodone/Naloxone Tablets (OXN) vs Codeine/Paracetamol Tablets · Mixed Models Analysis · p = 0.002 · Mean difference (net): 0.44
SecondaryNumber of Intakes of Rescue Medication (Ibuprofen) Between Visit 8 and Visit 9 for the 2 Groups.

To compare the number of intakes of rescue medication use (ibuprofen) for breakthrough pain between OXN (Oxycodone/Naloxone) and codeine/paracetamol groups. Ibuprofen tablets (400mg up to 3 times per day) were available as rescue medication. This was recorded by the subject in their diary whenever it was taken. The discrepancy in numbers of patients at this stage (between Visit 8 and Visit 9) is due to subject withdrawal during the study. The mean values presented are the "number of intakes of rescue medication" for this period (ie between Visit 8 and Visit 9).

Time frame:
Between visit 8 and 9
Reported as:
Mean · Number of rescue medication intakes
Number of Intakes of Rescue Medication (Ibuprofen) Between Visit 8 and Visit 9 for the 2 Groups.
Number of rescue medication intakesOxycodone/Naloxone Tablets (OXN)Codeine/Paracetamol Tablets
Number of Intakes of Rescue Medication (Ibuprofen) Between Visit 8 and Visit 9 for the 2 Groups.13.2 ± 23.319.4 ± 19.94

Adverse events

Collected over approximately 3 - 4 months, treatment and outcome. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oxycodone/Naloxone Tablets (OXN)—3/124 (2.4%)27/124 (21.8%)
Codeine/Paracetamol Tablets—4/123 (3.3%)32/123 (26%)
Most frequent serious events
Most frequent serious events
EventOxycodone/Naloxone Tablets (OXN)Codeine/Paracetamol Tablets
Deep vein thrombosisBlood and lymphatic system disorders0/1241/123
Head injfuryGeneral disorders0/1241/123
Atrial fibrillationCardiac disorders0/1241/123
Angina PectorisCardiac disorders0/1241/123
joint effusionMusculoskeletal and connective tissue disorders1/1240/123
carotid artery stenosisCardiac disorders1/1240/123
diarrhoea, rectal haemorrhage, abdominal painGastrointestinal disorders1/1240/123
Most frequent other events
Most frequent other events
EventOxycodone/Naloxone Tablets (OXN)Codeine/Paracetamol Tablets
ConstipationGastrointestinal disorders8/1247/123
lower respiratory tract infectionInfections and infestations7/1244/123
dyspepsiaGastrointestinal disorders4/1246/123
urinary tract infectionInfections and infestations2/1245/123
haemorrhoidsGastrointestinal disorders0/1244/123
nauseaGastrointestinal disorders4/1243/123
bronchitisInfections and infestations2/1243/123

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Oxycodone/Naloxone Tablets (OXN)Codeine/Paracetamol TabletsTotal
<=18 years000
Between 18 and 65 years6670136
>=65 years5853111
Age Continuous
Age Continuous(years)Oxycodone/Naloxone Tablets (OXN)Codeine/Paracetamol TabletsTotal
Mean64.3 ± 10.5363.9 ± 10.9764.1 ± 10.73
Sex: Female, Male
Sex: Female, Male(Participants)Oxycodone/Naloxone Tablets (OXN)Codeine/Paracetamol TabletsTotal
Female7781158
Male474289
Region of Enrollment
Region of Enrollment(participants)Oxycodone/Naloxone Tablets (OXN)Codeine/Paracetamol TabletsTotal
United Kingdom124123247
08

Study locations

1 site
  • Coventry, CV6 4DD, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Mar 2010 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2008
First posted
Nov 4, 2008
Start
Feb 2009
Primary completionActual
Mar 2010
CompletionActual
Jun 2011
Results first posted
Nov 2, 2011
Last update
Nov 2, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00784810
Lead sponsor
Napp Pharmaceuticals Limited
Responsible party
Sponsor
First posted
Nov 4, 2008
Start date
Feb 2009
Primary completion
Mar 2010
Completion
Jun 2011
Results posted
Nov 2, 2011
Last update
Nov 2, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxycodone · Naloxone

Start the discussion